अApnaFunda
Menu

WANBURY LIMITED (WANBURY)

Health Technology

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.44 / 100
Profitability 67Growth 63Balance sheet 2
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.26 / 100
Price 2Earnings 45FII/DII 31
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIES LIMITEDTORRENT PHARMACEUTICALS LTD
Share Price
₹189.21
P/E
14.4x
ROCE
37.0%
Market Cap
₹663 cr
Revenue (TTM)
₹629 cr
P/S
1.1x
P/B
11.2x
ROE
77.8%
Operating Margin
15.0%
Debt / Equity
3.0x
Promoter Holding
43.0%
12M Momentum
-28.0%
P/E vs its own history48th percentilesince Feb '19
P/E vs Health Technology0.4xthe sector median

52-week range

₹161.50₹358.85
14% of the way from its 52-week low to its high

Price risk

1Y volatility
54.5%
Beta vs sector
1-year daily
1.46

Balance sheet & cash

Interest cover
operating profit ÷ interest
2.2x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.65x
Share count, 1Y
unchanged

Was the rally earned?

-28%share price, 1 yearMultiple-driven

Mostly the multiple.

  • Most of the fall came from investors paying a lower multiple (P/E 20.1x to 14.4x); per-share earnings added 0 points.
  • The share count barely moved.
1 year P/E change: -28 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-28 pts -28% 1 year P/E change: -28 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-28 pts -28%
Net profit growth0 ptsNet profit was little changed.
P/E change-28 ptsThe P/E fell from 20.1x to 14.4x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+105%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 487 points, but investors now pay less per rupee of profit (P/E 196.4x to 14.4x), which took 382 points back.
  • The share count barely moved.
3 years Net profit growth: +487 pts. Points of the price return explained by net profit growing (or shrinking).+487 ptsP/E change: -382 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-382 pts +105% 3 years Net profit growth: +487 pts. Points of the price return explained by net profit growing (or shrinking).+487 ptsP/E change: -382 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.-382 pts +105%
Net profit growth+487 ptsNet profit rose about 2686%, which lifts the price.
P/E change-382 ptsThe P/E fell from 196.4x to 14.4x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

Is it expensive against its own past and its peers?

14.4xP/E todayWithin its usual range
Against its own history48th percentileMedian 15.2x; usual range 1.5x to 30.1x since 2019-02.
Against Health Technology14.4x vs 35.4xBelow the Health Technology median.
1.1x74.8x148.5x222.1xFeb '19Sep '20Apr '22Nov '23Jun '25Oct '261.1x74.8x148.5x222.1xFeb '19Sep '21Apr '24Oct '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dashed line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

What is the price implying?

~16%annual earnings growth implied by the price

At a P/E of 20.9x, the price would imply about 15.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Earnings figures have not updated recently, so the company is left out of the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

  1. Oct '26Fell 52% from the Jul 2026 peak to the Oct 2026 low.
  2. Oct '26Volume reached 6.0x its 50-day median on 2026-10-06; price +3.9% that day.
  3. Sep '26Slipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
  4. Jul '26Regained the 2024-12 peak, 16 months after the low.
  5. Jul '26Volume reached 74.6x its 50-day median on 2026-07-14; price +11.8% that day.
  6. Jun '26Year-on-year EPS growth turned positive.
  7. Jun '26Moved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
  8. Jun '26Volume reached 10.6x its 50-day median on 2026-06-01; price -13.6% that day.
Show 22 earlier events
  1. Jan '26Volume reached 26.3x its 50-day median on 2026-01-29; price +11.9% that day.
  2. Dec '25Promoter holding rose 3.5 pts to 43.1%.
  3. Oct '25Volume reached 8.6x its 50-day median on 2025-10-27; price +8.1% that day.
  4. Sep '25Slipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  5. Sep '25Volume reached 7.4x its 50-day median on 2025-09-16; price -0.7% that day.
  6. Jun '25Year-on-year EPS growth turned negative.
  7. Jun '25Moved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  8. May '25Volume reached 20.3x its 50-day median on 2025-05-16; price +9.8% that day.
  9. Mar '25Fell 50% from the Dec 2024 peak to the Mar 2025 low.
  10. Mar '25Volume reached 7.4x its 50-day median on 2025-03-24; price +10.1% that day.
  11. Dec '24Revenue (TTM) reached a new high of ₹577 cr.
  12. Dec '24Moved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  13. Dec '24Volume reached 6.4x its 50-day median on 2024-12-17; price +3.8% that day.
  14. Sep '24Year-on-year EPS growth turned positive.
  15. Sep '24Slipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
  16. Jul '24Regained the 2024-02 peak, 4 months after the low.
  17. Jul '24Volume reached 7.6x its 50-day median on 2024-07-16; price -0.2% that day.
  18. Jun '24Moved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  19. May '24Volume reached 8.2x its 50-day median on 2024-05-27; price +4.1% that day.
  20. Mar '24Fell 28% from the Feb 2024 peak to the Mar 2024 low.
  21. Feb '24Slipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  22. Jan '24Volume reached 18.9x its 50-day median on 2024-01-19; price +2.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

4 of 7 checks are within range, 2 near a threshold, 1 beyond a threshold.
Tap a check to see how it is measured.

Other income reliance12%Within range

Other income as a share of pre-tax profit (trailing twelve months): 11.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate1%Beyond threshold

Median quarterly effective tax rate over about 2.5 years: 1.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.65xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.65x (cash from operations ₹50 cr, net profit ₹77 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+11 daysWithin range

Debtor days are above the median of the previous three fiscal years by 11 days (70 vs 59). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress2% of fixed assetsWithin range

Capital work-in-progress is 2% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-24 days / 2 yrsWithin range

Days payable changed by -24 over two years. Bands: rise of up to 30 days; more than 30 days.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, promoters added 3.2 pts; FIIs added 0.9 pts.
  • The number of shareholders rose from 11,616 to 17,174 (+48%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters39.8%43.0%+3.2 pts
FIIs0.0%0.9%+0.9 pts
DIIs0.0%0.1%+0.1 pts
Public and others60.2%56.0%-4.2 pts

Number of shareholders

17,174shareholders+48% since Dec '23
12k14k16k18k Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 11,616
Mar '24: 13,087
Jun '24: 14,400
Sep '24: 17,199
Dec '24: 17,999
Mar '25: 17,889
Jun '25: 17,894
Sep '25: 17,717
Dec '25: 17,261
Mar '26: 16,732
Jun '26: 17,174
 12k14k16k18k Dec '23Dec '24Dec '25Jun '26
Dec '23: 11,616
Mar '24: 13,087
Jun '24: 14,400
Sep '24: 17,199
Dec '24: 17,999
Mar '25: 17,889
Jun '25: 17,894
Sep '25: 17,717
Dec '25: 17,261
Mar '26: 16,732
Jun '26: 17,174

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-69.5%recovered 2023-12
1-year volatility54.5%annualised
Beta vs sector index1.323-year daily, correlation 0.38
Volume spikes11last 90 sessions, 5x the 50-day median

Monthly share price

₹12₹111₹210₹309 Feb '19Sep '20Apr '22Nov '23Jun '25Oct '26
2019-02: ₹17.30
2019-03: ₹21.70
2019-04: ₹20.65
2019-05: ₹20.30
2019-06: ₹14.45
2019-07: ₹14.45
2019-08: ₹11.80
2019-09: ₹11.80
2019-10: ₹12.15
2019-11: ₹21.40
2019-12: ₹18.60
2020-01: ₹18.85
2020-02: ₹29.40
2020-03: ₹18.30
2020-04: ₹22.60
2020-05: ₹21.00
2020-06: ₹24.20
2020-07: ₹29.75
2020-08: ₹37.15
2020-09: ₹33.60
2020-10: ₹35.10
2020-11: ₹37.00
2020-12: ₹46.65
2021-01: ₹59.20
2021-02: ₹98.45
2021-03: ₹82.35
2021-04: ₹105.40
2021-05: ₹102.90
2021-06: ₹85.70
2021-07: ₹85.65
2021-08: ₹79.95
2021-09: ₹79.65
2021-10: ₹64.85
2021-11: ₹65.95
2021-12: ₹83.75
2022-01: ₹86.25
2022-02: ₹86.00
2022-03: ₹84.55
2022-04: ₹78.15
2022-05: ₹67.60
2022-06: ₹64.90
2022-07: ₹62.40
2022-08: ₹60.45
2022-09: ₹65.65
2022-10: ₹66.45
2022-11: ₹52.75
2022-12: ₹49.00
2023-01: ₹43.35
2023-02: ₹38.20
2023-03: ₹37.30
2023-04: ₹49.45
2023-05: ₹46.25
2023-06: ₹55.60
2023-07: ₹51.40
2023-08: ₹51.00
2023-09: ₹69.05
2023-10: ₹92.30
2023-11: ₹104.40
2023-12: ₹126.05
2024-01: ₹145.85
2024-02: ₹158.75
2024-03: ₹146.25
2024-04: ₹151.80
2024-05: ₹149.30
2024-06: ₹155.22
2024-07: ₹213.53
2024-08: ₹230.57
2024-09: ₹275.29
2024-10: ₹239.25
2024-11: ₹246.87
2024-12: ₹291.18
2025-01: ₹216.40
2025-02: ₹171.44
2025-03: ₹234.42
2025-04: ₹236.82
2025-05: ₹297.29
2025-06: ₹280.50
2025-07: ₹268.90
2025-08: ₹278.30
2025-09: ₹254.50
2025-10: ₹262.85
2025-11: ₹260.25
2025-12: ₹226.60
2026-01: ₹208.75
2026-02: ₹265.61
2026-03: ₹221.95
2026-04: ₹254.28
2026-05: ₹308.65
2026-06: ₹280.85
2026-07: ₹293.55
2026-08: ₹254.10
2026-09: ₹199.50
2026-10: ₹189.21
 ₹12₹111₹210₹309 Feb '19Sep '21Apr '24Oct '26
2019-02: ₹17.30
2019-03: ₹21.70
2019-04: ₹20.65
2019-05: ₹20.30
2019-06: ₹14.45
2019-07: ₹14.45
2019-08: ₹11.80
2019-09: ₹11.80
2019-10: ₹12.15
2019-11: ₹21.40
2019-12: ₹18.60
2020-01: ₹18.85
2020-02: ₹29.40
2020-03: ₹18.30
2020-04: ₹22.60
2020-05: ₹21.00
2020-06: ₹24.20
2020-07: ₹29.75
2020-08: ₹37.15
2020-09: ₹33.60
2020-10: ₹35.10
2020-11: ₹37.00
2020-12: ₹46.65
2021-01: ₹59.20
2021-02: ₹98.45
2021-03: ₹82.35
2021-04: ₹105.40
2021-05: ₹102.90
2021-06: ₹85.70
2021-07: ₹85.65
2021-08: ₹79.95
2021-09: ₹79.65
2021-10: ₹64.85
2021-11: ₹65.95
2021-12: ₹83.75
2022-01: ₹86.25
2022-02: ₹86.00
2022-03: ₹84.55
2022-04: ₹78.15
2022-05: ₹67.60
2022-06: ₹64.90
2022-07: ₹62.40
2022-08: ₹60.45
2022-09: ₹65.65
2022-10: ₹66.45
2022-11: ₹52.75
2022-12: ₹49.00
2023-01: ₹43.35
2023-02: ₹38.20
2023-03: ₹37.30
2023-04: ₹49.45
2023-05: ₹46.25
2023-06: ₹55.60
2023-07: ₹51.40
2023-08: ₹51.00
2023-09: ₹69.05
2023-10: ₹92.30
2023-11: ₹104.40
2023-12: ₹126.05
2024-01: ₹145.85
2024-02: ₹158.75
2024-03: ₹146.25
2024-04: ₹151.80
2024-05: ₹149.30
2024-06: ₹155.22
2024-07: ₹213.53
2024-08: ₹230.57
2024-09: ₹275.29
2024-10: ₹239.25
2024-11: ₹246.87
2024-12: ₹291.18
2025-01: ₹216.40
2025-02: ₹171.44
2025-03: ₹234.42
2025-04: ₹236.82
2025-05: ₹297.29
2025-06: ₹280.50
2025-07: ₹268.90
2025-08: ₹278.30
2025-09: ₹254.50
2025-10: ₹262.85
2025-11: ₹260.25
2025-12: ₹226.60
2026-01: ₹208.75
2026-02: ₹265.61
2026-03: ₹221.95
2026-04: ₹254.28
2026-05: ₹308.65
2026-06: ₹280.85
2026-07: ₹293.55
2026-08: ₹254.10
2026-09: ₹199.50
2026-10: ₹189.21

Last 90 trading days

₹166₹226₹285₹345 Jun 23Jul 20Aug 13Sep 8Oct 6Oct 30
2026-06-23: ₹282.70
2026-06-25: ₹274.35
2026-06-30: ₹280.85
2026-07-02: ₹286.75
2026-07-06: ₹283.65
2026-07-08: ₹270.85
2026-07-10: ₹297.85
2026-07-14: ₹336.00
2026-07-16: ₹343.20
2026-07-20: ₹339.90
2026-07-22: ₹330.65
2026-07-24: ₹331.90
2026-07-28: ₹312.45
2026-07-30: ₹297.65
2026-08-03: ₹286.20
2026-08-05: ₹278.80
2026-08-07: ₹254.95
2026-08-11: ₹254.30
2026-08-13: ₹251.10
2026-08-17: ₹250.70
2026-08-19: ₹269.55
2026-08-21: ₹264.85
2026-08-25: ₹264.35
2026-08-27: ₹254.65
2026-08-31: ₹254.10
2026-09-02: ₹245.00
2026-09-04: ₹246.20
2026-09-08: ₹247.70
2026-09-10: ₹241.45
2026-09-15: ₹223.10
2026-09-17: ₹223.65
2026-09-21: ₹227.55
2026-09-23: ₹233.10
2026-09-25: ₹224.15
2026-09-29: ₹216.95
2026-10-01: ₹197.99
2026-10-06: ₹197.87
2026-10-08: ₹194.20
2026-10-12: ₹192.05
2026-10-14: ₹191.06
2026-10-16: ₹192.36
2026-10-21: ₹187.67
2026-10-23: ₹178.47
2026-10-27: ₹176.02
2026-10-29: ₹181.93
2026-10-30: ₹189.21
 ₹166₹226₹285₹345 Jun 23Aug 5Sep 17Oct 30
2026-06-23: ₹282.70
2026-06-25: ₹274.35
2026-06-30: ₹280.85
2026-07-02: ₹286.75
2026-07-06: ₹283.65
2026-07-08: ₹270.85
2026-07-10: ₹297.85
2026-07-14: ₹336.00
2026-07-16: ₹343.20
2026-07-20: ₹339.90
2026-07-22: ₹330.65
2026-07-24: ₹331.90
2026-07-28: ₹312.45
2026-07-30: ₹297.65
2026-08-03: ₹286.20
2026-08-05: ₹278.80
2026-08-07: ₹254.95
2026-08-11: ₹254.30
2026-08-13: ₹251.10
2026-08-17: ₹250.70
2026-08-19: ₹269.55
2026-08-21: ₹264.85
2026-08-25: ₹264.35
2026-08-27: ₹254.65
2026-08-31: ₹254.10
2026-09-02: ₹245.00
2026-09-04: ₹246.20
2026-09-08: ₹247.70
2026-09-10: ₹241.45
2026-09-15: ₹223.10
2026-09-17: ₹223.65
2026-09-21: ₹227.55
2026-09-23: ₹233.10
2026-09-25: ₹224.15
2026-09-29: ₹216.95
2026-10-01: ₹197.99
2026-10-06: ₹197.87
2026-10-08: ₹194.20
2026-10-12: ₹192.05
2026-10-14: ₹191.06
2026-10-16: ₹192.36
2026-10-21: ₹187.67
2026-10-23: ₹178.47
2026-10-27: ₹176.02
2026-10-29: ₹181.93
2026-10-30: ₹189.21

Drawdown from peak

0% -34% -68% Feb '19Dec '22Oct '26 0% -34% -68% Feb '19Dec '22Oct '26
Largest drawdowns

-69.5% (2022-02 peak to 2023-03 low, recovered 2023-12)

-53.0% (2019-03 peak to 2019-10 low, recovered 2020-02)

-51.7% (2026-07 peak to 2026-10 low, not yet recovered)

Most recent volume spikes

2026-10-06: 6x the 50-day median, price +3.9% that day

2026-09-30: 5.5x the 50-day median, price -8.0% that day

2026-08-12: 12.1x the 50-day median, price +3.3% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26
Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

CompanySectorSimilarityClosest on
K P ENERGY (KPEL)Utilities52%ROCE, promoter holding
INDO AMINES (INDOAMIN)Process Industries50%operating margin, market cap
JAY BHARAT MARUTI (JAYBARMARU)Distribution Services46%revenue growth, EPS growth
SKM EGG PRODUCTS EXPORTS (INDI (SKMEGGPROD)Process Industries46%revenue growth, ROCE
BHARAT WIRE ROPES (BHARATWIRE)Producer Manufacturing45%revenue, promoter holding
HESTER BIOSCIENCES (HESTERBIO)Health Technology36%P/E, revenue growth
BETA DRUGS (BETA)Health Technology22%revenue, volatility
KILITCH DRUGS (I) (KILITCH)Health Technology22%market cap, revenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What happened next to similar setups

−11.8%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like WANBURY LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −32% to +47% vs the market, against −9% for all non-financial companies in the same months.
  • The gap against the base rate (−3.2%, 80% range −8.7% to +6.1%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
BEWLTD · May 2024: −57.1% vs market
HGINFRA · Oct 2025: −55.5% vs market
PAKKA · May 2025: −49.7% vs market
FOODSIN · Jan 2025: −48.9% vs market
RADIOCITY · Mar 2024: −46.0% vs market
PENINLAND · Nov 2024: −42.5% vs market
RUSHIL · Jun 2025: −40.6% vs market
RAJMET · May 2024: −39.7% vs market
DGCONTENT · Aug 2025: −38.7% vs market
ZODIAC · Oct 2025: −37.1% vs market
GEEKAYWIRE · Nov 2024: −35.5% vs market
BHARATWIRE · Aug 2024: −35.1% vs market
BAJAJHCARE · May 2023: −32.8% vs market
TRF · Feb 2025: −30.3% vs market
HUHTAMAKI · Dec 2024: −26.7% vs market
EMMBI · Oct 2025: −24.8% vs market
MAHESHWARI · Apr 2021: −21.3% vs market
INDIANHUME · Mar 2020: −20.2% vs market
ASHOKA · May 2021: −19.1% vs market
ASAL · Mar 2025: −18.0% vs market
DONEAR · May 2025: −16.7% vs market
HARIOMPIPE · Mar 2025: −15.2% vs market
KESORAMIND · Oct 2021: −13.9% vs market
ATMASTCO · May 2025: −13.7% vs market
NILAINFRA · Apr 2020: −12.1% vs market
BIGBLOC · Jan 2024: −11.5% vs market
STEELXIND · Dec 2024: −11.0% vs market
UTTAMSUGAR · Mar 2025: −1.4% vs market
AMBICAAGAR · Mar 2024: −1.4% vs market
INDOAMIN · Oct 2025: −0.8% vs market
FILATEX · May 2024: +3.2% vs market
KAMATHOTEL · Nov 2024: +8.9% vs market
SWSOLAR · Feb 2021: +16.8% vs market
SANSTAR · Jul 2025: +17.9% vs market
BIRLAMONEY · Mar 2020: +18.4% vs market
INSPIRISYS · May 2025: +18.7% vs market
SHIVATEX · Feb 2020: +25.1% vs market
BBOX · Aug 2025: +53.8% vs market
HCC · Mar 2021: +57.4% vs market
UNIVASTU · Sep 2021: +66.5% vs market
NDTV · Oct 2020: +69.9% vs market
MADHUSUDAN · Sep 2025: +70.5% vs market
DSSL · Jan 2024: +71.2% vs market
DPABHUSHAN · Jan 2023: +73.9% vs market
SBC · Jan 2025: +84.5% vs market
SKMEGGPROD · Mar 2025: +88.8% vs market
EVEREADY · Apr 2020: +174.7% vs market
REFEX · Jun 2024: +187.6% vs market
GVT&D · Dec 2022: +243.4% vs market
FACT · Sep 2022: +326.1% vs market
Similar setups −11.8%All companies −8.6%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median
−11.8%
All companies' median
−8.6%
Beat the market
40% vs 40%

50 past situations · 50 companies · 30 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
TRF
Producer Manufacturing		 Feb 2025 19x38% −26%−51% −30%
STEELXIND
Non-Energy Minerals		 Dec 2024 38x— −2%−42% −11%
BIRLAMONEY
Finance		 Mar 2020 11x— −59%−65% +18%
ZODIAC
Producer Manufacturing		 Oct 2025 27x— −36%−39% −37%
NDTV
Consumer Services		 Oct 2020 11x24% −11%−42% +70%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
INSPIRISYS
Technology Services		 May 2025 18x31% +7%−43% +19%
ASAL
Producer Manufacturing		 Mar 2025 39x46% −18%−55% −18%
DONEAR
Process Industries		 May 2025 12x— +3%−39% −17%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and size. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to WANBURY LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.
Monthly history (93 months)
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1014.4x₹629 cr77.8%37.0%3.0x
2026-0915.2x₹629 cr77.8%37.0%3.0x
2026-0819.4x₹629 cr77.8%37.0%3.0x
2026-0722.4x₹629 cr77.8%37.0%3.0x
2026-0621.4x₹629 cr77.8%37.0%3.0x
2026-0523.6x₹629 cr77.8%37.0%3.0x
2026-0419.4x₹629 cr77.8%37.0%3.0x
2026-0316.9x₹629 cr77.8%37.0%3.0x
2026-0220.3x₹629 cr77.8%37.0%3.0x
2026-0115.9x₹629 cr77.8%37.0%3.0x
2025-1217.3x₹629 cr77.8%37.0%3.0x
2025-1119.9x₹629 cr77.8%37.0%3.0x
2025-1020.1x₹629 cr77.8%37.0%3.0x
2025-0919.4x₹629 cr77.8%37.0%3.0x
2025-0829.9x₹597 cr55.6%37.0%3.0x
2025-0728.9x₹597 cr55.6%37.0%3.0x
2025-0630.1x₹597 cr55.6%37.0%3.0x
2025-0522.2x₹564 cr171.7%61.0%4.1x
2025-0417.7x₹564 cr171.7%61.0%4.1x
2025-0317.5x₹564 cr171.7%61.0%4.1x
2025-0210.6x₹577 cr206.8%61.0%4.1x
2025-0113.4x₹577 cr206.8%61.0%4.1x
2024-1218.0x₹577 cr206.8%61.0%4.1x
2024-1115.4x₹560 cr202.9%61.0%4.1x
2024-1015.0x₹560 cr202.9%61.0%4.1x
2024-0917.2x₹560 cr202.9%61.0%4.1x
2024-0813.5x₹575 cr218.5%61.0%4.1x
2024-0712.5x₹575 cr218.5%61.0%4.1x
2024-069.1x₹575 cr218.5%61.0%4.1x
2024-0520.9x₹569 cr—21.0%—
2024-0421.3x₹569 cr—21.0%—
2024-0320.5x₹569 cr—21.0%—
2024-0253.1x₹549 cr—21.0%—
2024-0148.8x₹549 cr—21.0%—
2023-1242.2x₹549 cr—21.0%—
2023-11222.1x₹529 cr—21.0%—
2023-10196.4x₹529 cr—21.0%—
2023-09146.9x₹529 cr—21.0%—
2023-08—₹500 cr—21.0%—
2023-07—₹500 cr—21.0%—
2023-06—₹500 cr—21.0%—
2023-051.9x₹511 cr—46.0%—
2023-042.0x₹511 cr—46.0%—
2023-031.5x₹511 cr—46.0%—
2023-021.5x₹511 cr—46.0%—
2023-011.7x₹511 cr—46.0%—
2022-122.0x₹511 cr—46.0%—
2022-112.1x₹511 cr—46.0%—
2022-102.7x₹511 cr—46.0%—
2022-092.6x₹511 cr—46.0%—
2022-082.4x₹511 cr—46.0%—
2022-072.5x₹511 cr—46.0%—
2022-062.6x₹511 cr—46.0%—
2022-05—₹392 cr—27.0%—
2022-04—₹392 cr—27.0%—
2022-03—₹392 cr—27.0%—
2022-02—₹392 cr—27.0%—
2022-01—₹392 cr—27.0%—
2021-12—₹392 cr—27.0%—
2021-11—₹392 cr—27.0%—
2021-10—₹392 cr—27.0%—
2021-09—₹392 cr—27.0%—
2021-08—₹392 cr—27.0%—
2021-07—₹392 cr—27.0%—
2021-06—₹392 cr—27.0%—
2021-054.0x₹367 cr—31.0%—
2021-044.1x₹367 cr—31.0%—
2021-033.2x₹367 cr—31.0%—
2021-023.8x₹367 cr—31.0%—
2021-012.3x₹367 cr—31.0%—
2020-121.8x₹367 cr—31.0%—
2020-111.4x₹367 cr—31.0%—
2020-101.4x₹367 cr—31.0%—
2020-091.3x₹367 cr—31.0%—
2020-081.4x₹367 cr—31.0%—
2020-071.2x₹367 cr—31.0%—
2020-06—₹367 cr—31.0%—
2020-05—₹391 cr—26.0%—
2020-04—₹391 cr—26.0%—
2020-03—₹391 cr—26.0%—
2020-02—₹391 cr—26.0%—
2020-01—₹391 cr—26.0%—
2019-12—₹391 cr—26.0%—
2019-11—₹391 cr—26.0%—
2019-10—₹391 cr—26.0%—
2019-09—₹391 cr—26.0%—
2019-08—₹391 cr—26.0%—
2019-07—₹391 cr—26.0%—
2019-06—₹391 cr—26.0%—
2019-05—₹370 cr—-1.0%—
2019-04—₹370 cr—-1.0%—
2019-03—₹370 cr—-1.0%—
2019-02—₹370 cr—-1.0%—

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback